Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

aTyr Pharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights – ATYR

Key Takeaway: Levi & Korsinsky, LLP has initiated a class action lawsuit against aTyr Pharma, Inc. for alleged securities fraud affecting investors between November 7, 2024, and September 12, 2025. The complaint claims the company made misleading statements about the effectiveness of its drug, Efzofitimod, particularly related to steroid tapering. The lawsuit follows the disclosure that aTyr's EFZO-FIT study did not meet its primary endpoint, leading to a severe decline in share price. Investors have until December 8, 2025, to apply as lead plaintiff in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • aTyr Pharma is facing a class action lawsuit for alleged securities fraud.
  • The company reportedly misled investors about the efficacy of Efzofitimod.
  • The share price plummeted by 83.2% following the announcement of failed study results.
  • The lawsuit covers a significant period where the company's optimistic statements contradicted actual performance.

Full Press Release Details

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between November 7, 2024 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team:
ATYR investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. The truth emerged on September 15, 2025 (pre-market) when aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint. In pertinent part, defendants announced that the study did not meet the primary endpoint in change from baseline in mean daily OSC dose at week 48. Additionally, aTyr announced that the Company’s next step was to engage with the FDA to determine a path forward, given the disappointing topline results. Following this news, the price of aTyr’s common stock declined from a closing market price of $6.03 per share on September 12, 2025 to $1.02 per share on September 15, 2025, a decline of 83.2% in the span of just a single day.
WHAT'S NEXT? If you suffered a loss in aTyr during the relevant time frame, you have until December 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the aTyr Pharma class action lawsuit about?

The lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud.

When did the alleged fraud occur for aTyr Pharma?

The fraudulent activities are claimed to have occurred between November 7, 2024 and September 12, 2025.

What caused aTyr's stock price to drop significantly?

aTyr's stock plummeted after revealing its EFZO-FIT study did not achieve the primary endpoint.

What is the deadline to apply as lead plaintiff in the lawsuit?

Investors have until December 8, 2025, to request their appointment as lead plaintiff.

Will investors have to pay costs to participate in the lawsuit?

Class members may be eligible for compensation without any out-of-pocket costs or fees.

Last updated: Nov 25, 2025